Kevin is a Vice President on the Frazier Life Sciences team focused on identifying and evaluating new investment opportunities in public companies.
Kevin joined the Frazier Life Sciences team in 2021, where he focuses on identifying and evaluating new public investment opportunities.
Kevin was previously a resident physician in Internal Medicine at Stanford, where he cared for patients at Stanford University Medical Center and affiliated clinics. He has published over 15 peer-reviewed research articles on healthcare outcomes and utilization, clinical informatics, and quantitative pathology. During medical school, he also worked in life sciences investing as a summer associate at Frazier and at Acuta Capital.
Before his medical training, Kevin was a consultant at McKinsey and Company, where he worked with clients in the hospital services and pharmaceutical industries on corporate strategy, growth, and mergers and acquisitions.
Kevin received his M.D. from Stanford University and his B.S. from Yale University, where he graduated summa cum laude in Molecular Biophysics and Biochemistry and was a member of Phi Beta Kappa.
Stanford University (M.D.)
Yale University (B.S.)